



65 West Watkins Mill Road
Gaithersburg, MD 20878
tel: 240-632-0740
fax: 240-632-0735
www.genvec.com

FOR IMMEDIATE RELEASE:

Investor Contact:

GenVec, Inc.
Danielle M. DiPirro
(301) 944-1877
ddipirro@genvec.com

Media Contact:

Tiberend Strategic Advisors, Inc.
Andrew Mielach
(212) 827-0020
amielach@tiberendstrategicadvisors.com

**GENVEC TO PRESENT AT THE 12TH ANNUAL
BIO CEO & INVESTOR CONFERENCE**

GAITHERSBURG, MD – February 1, 2010 – GenVec, Inc. (NASDAQ: GNVC) today announced that Paul H. Fischer, Ph.D., GenVec’s President and CEO, will present a company overview highlighting recent developments at the 12th Annual BIO CEO & Investor Conference on Monday, February 8, 2010 at 1:30 p.m. EST at the Waldorf Astoria Hotel in New York City.

A webcast of Dr. Fischer’s presentation will be available both live and on replay. To access either the live or archived webcast, log on to GenVec’s website at www.genvec.com, click on “Investor Relations,” and proceed to “Webcasts & Data.” The replay will be available 24 hours after the live presentation and will be accessible for 30 days.

About GenVec

GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines. GenVec’s lead product, TNFerade™, is currently in a pivotal clinical study (PACT) in locally advanced pancreatic cancer. TNFerade has also been and is currently being evaluated for its potential use in the treatment of several other cancers, including esophageal cancer, rectal cancer, and head and neck cancer. In addition, GenVec uses its proprietary adenovector technology to develop vaccines for infectious diseases including influenza, HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and HSV-2. GenVec also discovers and develops novel treatments for hearing loss and balance disorders through a worldwide collaboration with Novartis. Additional information about GenVec is available at www.genvec.com and in the company’s various filings with the Securities and Exchange Commission.

###